JO3439B1 - مشتقات كربامات/يوريا - Google Patents

مشتقات كربامات/يوريا

Info

Publication number
JO3439B1
JO3439B1 JOP/2013/0218A JOP20130218A JO3439B1 JO 3439 B1 JO3439 B1 JO 3439B1 JO P20130218 A JOP20130218 A JO P20130218A JO 3439 B1 JO3439 B1 JO 3439B1
Authority
JO
Jordan
Prior art keywords
carbamate
urea derivatives
urea
derivatives
medicaments
Prior art date
Application number
JOP/2013/0218A
Other languages
Arabic (ar)
English (en)
Inventor
J Troxler Thomas
Zhang Xuechun
Jiang Haiyang
Kay Dodd Stephanie
Wang Tielin
Wang Xiaoyang
Curzi Marco
Luca Giaffreda Stefano
H Karpinski Piotr
Gary Bock Mark
Auberson Yves
Brage Dario
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49263333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3439(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3439B1 publication Critical patent/JO3439B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JOP/2013/0218A 2012-07-20 2013-07-21 مشتقات كربامات/يوريا JO3439B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2012078933 2012-07-20
CN2013078309 2013-06-28

Publications (1)

Publication Number Publication Date
JO3439B1 true JO3439B1 (ar) 2019-10-20

Family

ID=49263333

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0218A JO3439B1 (ar) 2012-07-20 2013-07-21 مشتقات كربامات/يوريا

Country Status (41)

Country Link
US (4) US9034874B2 (enExample)
EP (1) EP2875016B1 (enExample)
JP (1) JP6203841B2 (enExample)
KR (1) KR102150739B1 (enExample)
CN (1) CN104470911B (enExample)
AP (1) AP3710A (enExample)
AR (1) AR092354A1 (enExample)
AU (1) AU2013291617B2 (enExample)
BR (1) BR112015001207B1 (enExample)
CA (1) CA2878006C (enExample)
CL (1) CL2015000056A1 (enExample)
CO (1) CO7170173A2 (enExample)
CR (1) CR20150019A (enExample)
CU (1) CU24248B1 (enExample)
CY (1) CY1119492T1 (enExample)
DK (1) DK2875016T3 (enExample)
EA (1) EA026091B1 (enExample)
ES (1) ES2648512T3 (enExample)
GT (1) GT201500012A (enExample)
HR (1) HRP20171692T1 (enExample)
HU (1) HUE035592T2 (enExample)
IL (1) IL236656A (enExample)
IN (1) IN2014DN10449A (enExample)
JO (1) JO3439B1 (enExample)
LT (1) LT2875016T (enExample)
MX (1) MX362059B (enExample)
MY (1) MY168752A (enExample)
NO (1) NO2875016T3 (enExample)
NZ (1) NZ702346A (enExample)
PE (1) PE20151155A1 (enExample)
PH (1) PH12014502743B1 (enExample)
PL (1) PL2875016T3 (enExample)
PT (1) PT2875016T (enExample)
RS (1) RS56479B1 (enExample)
SG (2) SG11201408020RA (enExample)
SI (1) SI2875016T1 (enExample)
TN (1) TN2014000497A1 (enExample)
TW (1) TWI597276B (enExample)
UY (1) UY34921A (enExample)
WO (1) WO2014013469A1 (enExample)
ZA (1) ZA201408805B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
EP3391886A1 (en) * 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
WO2019245975A1 (en) 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
CN112789038A (zh) 2018-10-11 2021-05-11 诺华股份有限公司 H3r反向激动剂用于治疗与帕金森病(pd)相关的日间过度嗜睡的用途
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
US12616702B2 (en) 2019-12-03 2026-05-05 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
EP4251148A1 (en) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
TW301607B (enExample) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
IL150650A0 (en) 2000-01-20 2003-02-12 Eisai Co Ltd Piperidine derivatives and pharmaceutical compositions containing the same
JP4522651B2 (ja) 2001-03-13 2010-08-11 シェーリング コーポレイション 新規非イミダゾール化合物
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
HRP20080541T3 (en) 2003-04-23 2008-12-31 Glaxo Group Limited Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
BRPI0507629A (pt) 2004-02-13 2007-07-03 Banyu Pharma Co Ltd composto, antagonista do receptor e agonista inverso do receptor da histamina h3, agente profilático ou terapêutico para uma doença metabólica, uma doença circulatória ou uma doença do sistema nervoso, ou um seu sal farmaceuticamente aceitável
SE0401971D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
KR20090102883A (ko) 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
WO2006029056A1 (en) 2004-09-02 2006-03-16 Teva Pharmaceutical Industries Ltd. Preparation of olmesartan medoxomil
WO2007016496A2 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
JP2009514846A (ja) 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
WO2007063934A1 (ja) 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 脂環式複素環化合物
US8093248B2 (en) * 2007-12-05 2012-01-10 Astrazeneca Ab (Publ) Compounds useful for the treatment of conditions associated with weight gain
TWI498115B (zh) * 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
JP5677325B2 (ja) 2010-01-22 2015-02-25 大鵬薬品工業株式会社 Pgds阻害作用を有するピペラジン化合物
TW201217312A (en) * 2010-09-22 2012-05-01 Gruenenthal Gmbh Substituted benzamide compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives

Also Published As

Publication number Publication date
TN2014000497A1 (en) 2016-03-30
MX2015000903A (es) 2015-04-10
MX362059B (es) 2019-01-07
IL236656A (en) 2017-12-31
IL236656A0 (en) 2015-02-26
CL2015000056A1 (es) 2015-03-20
PH12014502743A1 (en) 2015-02-02
CN104470911B (zh) 2018-04-06
MY168752A (en) 2018-11-30
PH12014502743B1 (en) 2015-02-02
CY1119492T1 (el) 2018-03-07
AP2014008109A0 (en) 2014-12-31
AR092354A1 (es) 2015-04-15
JP6203841B2 (ja) 2017-09-27
HRP20171692T1 (hr) 2017-12-15
CA2878006A1 (en) 2014-01-23
TWI597276B (zh) 2017-09-01
US9273026B2 (en) 2016-03-01
AU2013291617A1 (en) 2015-01-15
PE20151155A1 (es) 2015-08-05
BR112015001207A8 (pt) 2018-01-16
HUE035592T2 (en) 2018-05-28
NZ702346A (en) 2017-06-30
CA2878006C (en) 2020-10-27
US9624192B2 (en) 2017-04-18
KR102150739B1 (ko) 2020-09-02
IN2014DN10449A (enExample) 2015-08-21
US9034874B2 (en) 2015-05-19
PL2875016T3 (pl) 2018-01-31
ZA201408805B (en) 2016-08-31
CR20150019A (es) 2015-05-04
CO7170173A2 (es) 2015-01-28
US20170275264A1 (en) 2017-09-28
US20140163036A1 (en) 2014-06-12
AU2013291617B2 (en) 2015-10-01
PT2875016T (pt) 2017-11-30
US20160244426A1 (en) 2016-08-25
RS56479B1 (sr) 2018-01-31
GT201500012A (es) 2017-11-09
EP2875016B1 (en) 2017-08-23
BR112015001207A2 (pt) 2017-08-01
EP2875016A1 (en) 2015-05-27
US20150218127A1 (en) 2015-08-06
UY34921A (es) 2014-02-28
KR20150036081A (ko) 2015-04-07
EA026091B1 (ru) 2017-02-28
EA201590250A1 (ru) 2015-05-29
ES2648512T3 (es) 2018-01-03
SI2875016T1 (sl) 2017-11-30
HK1204609A1 (en) 2015-11-27
LT2875016T (lt) 2017-11-10
CU24248B1 (es) 2017-02-02
NO2875016T3 (enExample) 2018-01-20
BR112015001207B1 (pt) 2022-08-09
WO2014013469A1 (en) 2014-01-23
CU20150006A7 (es) 2016-02-29
SG11201408020RA (en) 2015-03-30
JP2015522606A (ja) 2015-08-06
DK2875016T3 (da) 2017-11-27
TW201408656A (zh) 2014-03-01
CN104470911A (zh) 2015-03-25
SG10201700188PA (en) 2017-02-27
AP3710A (en) 2016-05-31

Similar Documents

Publication Publication Date Title
PH12014502743A1 (en) Carbamate/urea derivatives
IN2015DN03998A (enExample)
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12013500473A1 (en) Triazine-oxadiazoles
IN2012DN01269A (enExample)
UY33541A (es) N-((6-amino-piridin-3-il)-metil)-heteroaril-carboxamidas
MY173843A (en) Amidine substituted ?-lactam compounds, their preparation and use as antibacterial agents
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12018501709A1 (en) Naphthridinedione derivatives
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
EA201591064A1 (ru) Новые производные пиридина
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
IN2014DN01629A (enExample)
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
MX2014015345A (es) Inhibidores piranopiridona de tanquirasa.
IN2014DN10669A (enExample)
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
WO2015002755A3 (en) Compounds for the treatment of malaria
MX2013007726A (es) Derivados de 2-metoxi-piridin-4-ilo.
PH12015500373A1 (en) Diazepinone derivatives useful for the treatment of fragile x syndrome, parkinsons or reflux disease
MA37778A1 (fr) Dérivés de carbamate/urée
TN2013000089A1 (en) Triazine-oxadiazoles
PL402030A1 (pl) Nowe pochodne tiosemikarbazonów, ich kompozycje farmaceutyczne oraz ich zastosowanie
TN2013000327A1 (en) Novel heterocyclic derivatives